Compare Johnson & Johnson (JNJ) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs UiPath Inc — how do they compare? Johnson & Johnson trades at $260.02 (market cap $630.94B), while UiPath Inc trades at $15.66 (market cap $8.08B). The key difference: Johnson & Johnson is far larger — about 78.1× UiPath Inc's market cap, and Johnson & Johnson pays a 2.05% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| JNJ | PATH | |
|---|---|---|
Market Cap | $630.94B | $8.08B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $19.29 |
52-Week Low | $172.78 | $9.38 |
Enterprise Value | $659.21B | $6.85B |
Dividend Yield | 2.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.
JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).
UiPath (PATH) trades at $15.05, up 7.5% amid an AI stock rally, with technical indicators showing bullish momentum despite an overbought RSI. The company demonstrates strong revenue growth, improving from $892M in 2022 to $1.43B in 2025, with net income turning positive in 2026. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beating estimates. Analyst sentiment remains cautious with a $13.33 consensus target below current price.
PATH offers exposure to enterprise automation growth with improving profitability, but faces execution risks and competitive pressures. The stock trades at premium valuations (P/E 25.08, P/S 4.86) while cash flow trends show improvement from negative $182M in 2025 to projected negative $67M in 2026. Key risks include AI competition and software spending volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
